Back to top
more

Harmony Biosciences (HRMY)

(Delayed Data from NSDQ)

$29.70 USD

29.70
293,285

-0.16 (-0.54%)

Updated May 15, 2024 04:00 PM ET

After-Market: $29.69 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HRMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 353 323 234 229 24
Receivables 74 55 35 22 4
Notes Receivable 0 0 0 0 0
Inventories 5 4 4 4 1
Other Current Assets 18 18 11 8 2
Total Current Assets 451 400 284 263 32
Net Property & Equipment 0 1 1 1 1
Investments & Advances 72 23 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 144 86 0 0 0
Intangibles 137 161 144 162 72
Deposits & Other Assets 7 4 4 1 2
Total Assets 811 674 433 427 107
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 18 4 1 3 6
Current Portion Long-Term Debt 15 2 2 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 123 71 49 132 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 8 2 1 0 0
Total Current Liabilities 164 79 54 135 20
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 179 190 190 194 98
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 3 3 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 344 271 247 330 118
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 411
Common Stock (Par) 0 0 0 0 0
Capital Surplus 610 675 640 585 0
Retained Earnings -143 -272 -454 -488 -423
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 467 403 187 97 -12
Total Liabilities & Shareholder's Equity 811 674 433 427 107
Total Common Equity 467 403 187 97 -423
Shares Outstanding 58.50 59.30 58.40 56.80 NA
Book Value Per Share 7.98 6.79 3.19 1.71 0.00

Fiscal Year End for Harmony Biosciences Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 372 353 371 371 344
Receivables 80 74 67 64 53
Notes Receivable 0 0 0 0 0
Inventories 6 5 5 5 4
Other Current Assets 22 18 20 16 18
Total Current Assets 480 451 463 456 418
Net Property & Equipment 0 0 0 1 0
Investments & Advances 81 72 68 59 49
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 148 144 100 94 89
Intangibles 131 137 143 149 155
Deposits & Other Assets 7 7 3 3 4
Total Assets 847 811 778 760 715
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 15 18 7 7 6
Current Portion Long-Term Debt 15 15 15 11 7
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 99 123 83 72 63
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 25 8 8 4 10
Total Current Liabilities 154 164 112 93 85
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 175 179 182 180 185
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 1 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 332 344 296 275 272
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 621 610 652 694 686
Retained Earnings -105 -143 -170 -208 -243
Other Equity 0 0 -1 -1 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 515 467 481 485 443
Total Liabilities & Shareholder's Equity 847 811 778 760 715
Total Common Equity 515 467 481 485 443
Shares Outstanding 56.70 58.50 58.50 60.00 59.90
Book Value Per Share 9.09 7.98 8.23 8.09 7.40